Search

Your search keyword '"Jager, Kitty"' showing total 1,732 results
Start Over Author "Jager, Kitty"
1,732 results on '"Jager, Kitty"'

2. Causal prediction models for medication safety monitoring: The diagnosis of vancomycin-induced acute kidney injury

Author

Kom, Izak Yasrebi-de, Klopotowska, Joanna, Dongelmans, Dave, De Keizer, Nicolette, Jager, Kitty, Abu-Hanna, Ameen, and Cinà, Giovanni

Subjects
Computer Science - Machine Learning, Statistics - Methodology
Abstract

The current best practice approach for the retrospective diagnosis of adverse drug events (ADEs) in hospitalized patients relies on a full patient chart review and a formal causality assessment by multiple medical experts. This evaluation serves to qualitatively estimate the probability of causation (PC); the probability that a drug was a necessary cause of an adverse event. This practice is manual, resource intensive and prone to human biases, and may thus benefit from data-driven decision support. Here, we pioneer a causal modeling approach using observational data to estimate a lower bound of the PC (PC$_{low}$). This method includes two key causal inference components: (1) the target trial emulation framework and (2) estimation of individualized treatment effects using machine learning. We apply our method to the clinically relevant use-case of vancomycin-induced acute kidney injury in intensive care patients, and compare our causal model-based PC$_{low}$ estimates to qualitative estimates of the PC provided by a medical expert. Important limitations and potential improvements are discussed, and we conclude that future improved causal models could provide essential data-driven support for medication safety monitoring in hospitalized patients., Comment: Extended Abstract presented at Machine Learning for Health (ML4H) symposium 2023, December 10th, 2023, New Orleans, United States, 14 pages

Published
2023

4. National health policies and strategies for addressing chronic kidney disease: Data from the International Society of Nephrology Global Kidney Health Atlas.

Author

Neuen, Brendon, Bello, Aminu, Levin, Adeera, Lunney, Meaghan, Osman, Mohamed, Ye, Feng, Ashuntantang, Gloria, Bellorin-Font, Ezequiel, Gharbi, Mohammed, Davison, Sara, Ghnaimat, Mohammad, Harden, Paul, Jha, Vivekanand, Kalantar-Zadeh, Kamyar, Kerr, Peter, Klarenbach, Scott, Kovesdy, Csaba, Luyckx, Valerie, Ossareh, Shahrzad, Perl, Jeffrey, Rashid, Harun, Rondeau, Eric, See, Emily, Saad, Syed, Sola, Laura, Tchokhonelidze, Irma, Tesar, Vladimir, Tungsanga, Kriang, Kazancioglu, Rumeyza, Wang, Angela, Yang, Chih-Wei, Zemchenkov, Alexander, Zhao, Ming-Hui, Jager, Kitty, Caskey, Fergus, Perkovic, Vlado, Jindal, Kailash, Okpechi, Ikechi, Tonelli, Marcello, Feehally, John, Harris, David, and Johnson, David

Abstract

National strategies for addressing chronic kidney disease (CKD) are crucial to improving kidney health. We sought to describe country-level variations in non-communicable disease (NCD) strategies and CKD-specific policies across different regions and income levels worldwide. The International Society of Nephrology Global Kidney Health Atlas (GKHA) was a multinational cross-sectional survey conducted between July and October 2018. Responses from key opinion leaders in each country regarding national NCD strategies, the presence and scope of CKD-specific policies, and government recognition of CKD as a health priority were described overall and according to region and income level. 160 countries participated in the GKHA survey, comprising 97.8% of the worlds population. Seventy-four (47%) countries had an established national NCD strategy, and 53 (34%) countries reported the existence of CKD-specific policies, with substantial variation across regions and income levels. Where CKD-specific policies existed, non-dialysis CKD care was variably addressed. 79 (51%) countries identified government recognition of CKD as a health priority. Low- and low-middle income countries were less likely to have strategies and policies for addressing CKD and have governments which recognise it as a health priority. The existence of CKD-specific policies, and a national NCD strategy more broadly, varied substantially across different regions around the world but was overall suboptimal, with major discrepancies between the burden of CKD in many countries and governmental recognition of CKD as a health priority. Greater recognition of CKD within national health policy is critical to improving kidney healthcare globally.

Published
2023

5. Associations of longitudinal height and weight with clinical outcomes in pediatric kidney replacement therapy: results from the ESPN/ERA Registry

Author

Bonthuis, Marjolein, Bakkaloglu, Sevcan A., Vidal, Enrico, Baiko, Sergey, Braddon, Fiona, Errichiello, Carmela, Francisco, Telma, Haffner, Dieter, Lahoche, Annie, Leszczyńska, Beata, Masalkiene, Jurate, Stojanovic, Jelena, Molchanova, Maria S., Reusz, George, Barba, Adela Rodriguez, Rosales, Alejandra, Tegeltija, Sanja, Ylinen, Elisa, Zlatanova, Galia, Harambat, Jérôme, and Jager, Kitty J.

Published
2023
Full Text
View/download PDF

6. Sex differences in COVID-19 mortality risk in patients on kidney function replacement therapy

Author

Vart, Priya, Duivenvoorden, Raphaël, Adema, Aaltje, Covic, Adrian, Finne, Patrik, Braak, Nicole Heijtink-ter, Laine, Kaisa, Noordzij, Marlies, Schouten, Marcel, Jager, Kitty J, and Gansevoort, Ron T

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Transplantation, Prevention, Kidney Disease, Organ Transplantation, Renal and urogenital, Good Health and Well Being, Humans, Female, Male, Middle Aged, Aged, COVID-19, Renal Dialysis, Kidney Transplantation, Sex Characteristics, Risk Factors, Immunosuppressive Agents, Kidney, ERACODA Collaborators
Abstract

In the general population with COVID-19, the male sex is an established risk factor for mortality, in part due to a more robust immune response to COVID-19 in women. Because patients on kidney function replacement therapy (KFRT) have an impaired immune response, especially kidney transplant recipients due to their use of immunosuppressants, we examined whether the male sex is still a risk factor for mortality among patients on KFRT with COVID-19. From the European Renal Association COVID-19 Database (ERACODA), we examined patients on KFRT with COVID-19 who presented between February 1st, 2020, and April 30th, 2021. 1204 kidney transplant recipients (male 62.0%, mean age 56.4 years) and 3206 dialysis patients (male 61.8%, mean age 67.7 years) were examined. Three-month mortality in kidney transplant recipients was 16.9% in males and 18.6% in females (p = 0.31) and in dialysis patients 27.1% in males and 21.9% in females (p = 0.001). The adjusted HR for the risk of 3-month mortality in males (vs females) was 0.89 (95% CI 65, 1.23, p = 0.49) in kidney transplant recipients and 1.33 (95% CI 1.13, 1.56, p = 0.001) in dialysis patients (pinteraction = 0.02). In a fully adjusted model, the aHR for the risk of 3-month mortality in kidney transplant recipients (vs. dialysis patients) was 1.39 (95% CI 1.02, 1.89, p = 0.04) in males and 2.04 (95% CI 1.40, 2.97, p

Published
2022

7. Association of obesity with 3-month mortality in kidney failure patients with COVID-19.

Author

Tantisattamo, Ekamol, Imhof, Celine, Jager, Kitty J, Hilbrands, Luuk B, Guidotti, Rebecca, Islam, Mahmud, Katicic, Dajana, Konings, Constantijn, Molenaar, Femke M, Nistor, Ionut, Noordzij, Marlies, Rodríguez Ferrero, María Luisa, Verhoeven, Martine AM, de Vries, Aiko PJ, Kalantar-Zadeh, Kamyar, Gansevoort, Ron T, Vart, Priya, and ERACODA collaborators

Subjects
ERACODA collaborators, COVID-19, kidney failure, mortality, obesity paradox, reverse epidemiology, Kidney Disease, Obesity, Nutrition, Prevention, Renal and urogenital, Good Health and Well Being
Abstract

BackgroundIn the general population with coronavirus disease 2019 (COVID-19), obesity is associated with an increased risk of mortality. Given the typically observed obesity paradox among patients on kidney function replacement therapy (KFRT), especially dialysis patients, we examined the association of obesity with mortality among dialysis patients or living with a kidney transplant with COVID-19.MethodsData from the European Renal Association COVID-19 Database (ERACODA) were used. KFRT patients diagnosed with COVID-19 between 1 February 2020 and 31 January 2021 were included. The association of Quetelet's body mass index (BMI) (kg/m2), divided into:

Published
2022

8. Recovery of dialysis patients with COVID-19: health outcomes 3 months after diagnosis in ERACODA

Author

Hemmelder, Marc H, Noordzij, Marlies, Vart, Priya, Hilbrands, Luuk B, Jager, Kitty J, Abrahams, Alferso C, Arroyo, David, Battaglia, Yuri, Ekart, Robert, Mallamaci, Francesca, Malloney, Sharon-Rose, Oliveira, Joao, Rydzewski, Andrzej, Sridharan, Sivakumar, Vogt, Liffert, Duivenvoorden, Raphaël, Gansevoort, Ron T, Franssen, Casper FM, van der Net, Jeroen B, Essig, Marie, du Buf-Vereijken, Peggy WG, van Ginneken, Betty, Maas, Nanda, van Jaarsveld, Brigit C, Bemelman, Frederike J, Klingenberg-Salahova, Farah, Heenan-Vos, Frederiek, Vervloet, Marc G, Nurmohamed, Azam, Abramowicz, Daniel, Verhofstede, Sabine, Maoujoud, Omar, Malfait, Thomas, Fialova, Jana, Melilli, Edoardo, Favà, Alexandre, Cruzado, Josep M, Perez, Nuria Montero, Lips, Joy, Krepel, Harmen, Adilovic, Harun, Hengst, Maaike, Konings, Constantijn JAM, Braconnier, Philippe, Weis, Daniel, Gellert, Ryszard, Alferes, Daniela G, Radulescu, Daniela, Zakharova, Elena V, Ambuehl, Patrice Max, Guidotti, Rebecca, Walker, Andrea, Lepeytre, Fanny, Rabaté, Clémentine, Rostoker, Guy, Marques, Sofia, Azasevac, Tijana, Majstorovic, Gordana Strazmester, Katicic, Dajana, Dam, Marc ten, Krüger, Thilo, Brzosko, Szymon, Liakopoulos, Vassilios, Zanen, Adriaan L, Logtenberg, Susan JJ, Fricke, Lutz, Kuryata, Olexandr, Slebe, Jeroen JP, ElHafeez, Samar Abd, Kemlin, Delphine, van de Wetering, Jacqueline, Reinders, Marlies EJ, Hesselink, Dennis A, van Gestel, J Kal-, Eiselt, Jaromir, Kielberger, Lukas, El-Wakil, Hala S, Verhoeven, Martine AM, Logan, Ian, Canal, Cristina, Facundo, Carme, Ramos, Ana M, Debska-Slizien, Alicja, Veldhuizen, Nicoline MH, Tigka, Eirini, Konsta, Maria Anna Polyzou, Panagoutsos, Stylianos, Postorino, Adele, Cambareri, Francesco, Matceac, Irina, Nistor, Ionut, Covic, Adrian, Groeneveld, JHM, Jousma, Jolanda, van Buren, Marjolijn, Diekmann, Fritz, Oppenheimer, Federico, Blasco, Miquel, Pereira, Tiago Assis, and dos Santos, Augusto Cesar Soares

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Kidney Disease, Patient Safety, Clinical Research, 4.1 Discovery and preclinical testing of markers and technologies, Detection, screening and diagnosis, Good Health and Well Being, Aged, Aged, 80 and over, COVID-19, COVID-19 Testing, Female, Humans, Intensive Care Units, Male, Middle Aged, Outcome Assessment, Health Care, Renal Dialysis, SARS-CoV-2, ERACODA Collaborators, dialysis, functional health status, mental health status, survival, Urology & Nephrology, Clinical sciences
Abstract

BackgroundCoronavirus disease 2019 (COVID-19)-related short-term mortality is high in dialysis patients, but longer-term outcomes are largely unknown. We therefore assessed patient recovery in a large cohort of dialysis patients 3 months after their COVID-19 diagnosis.MethodsWe analyzed data on dialysis patients diagnosed with COVID-19 from 1 February 2020 to 31 March 2021 from the European Renal Association COVID-19 Database (ERACODA). The outcomes studied were patient survival, residence and functional and mental health status (estimated by their treating physician) 3 months after COVID-19 diagnosis. Complete follow-up data were available for 854 surviving patients. Patient characteristics associated with recovery were analyzed using logistic regression.ResultsIn 2449 hemodialysis patients (mean ± SD age 67.5 ± 14.4 years, 62% male), survival probabilities at 3 months after COVID-19 diagnosis were 90% for nonhospitalized patients (n = 1087), 73% for patients admitted to the hospital but not to an intensive care unit (ICU) (n = 1165) and 40% for those admitted to an ICU (n = 197). Patient survival hardly decreased between 28 days and 3 months after COVID-19 diagnosis. At 3 months, 87% functioned at their pre-existent functional and 94% at their pre-existent mental level. Only few of the surviving patients were still admitted to the hospital (0.8-6.3%) or a nursing home (∼5%). A higher age and frailty score at presentation and ICU admission were associated with worse functional outcome.ConclusionsMortality between 28 days and 3 months after COVID-19 diagnosis was low and the majority of patients who survived COVID-19 recovered to their pre-existent functional and mental health level at 3 months after diagnosis.

Published
2022

9. Clinical, Functional, and Mental Health Outcomes in Kidney Transplant Recipients 3 Months After a Diagnosis of COVID-19

Author

Duivenvoorden, Raphaël, Vart, Priya, Noordzij, Marlies, dos Santos, Augusto C Soares, Zulkarnaev, Alex B, Franssen, Casper FM, Kuypers, Dirk, Demir, Erol, Rahimzadeh, Hormat, Kerschbaum, Julia, Jager, Kitty J, Turkmen, Kultigin, Hemmelder, Marc H, Schouten, Marcel, Rodríguez-Ferrero, María Luisa, Crespo, Marta, Gansevoort, Ron T, and Hilbrands, Luuk B

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Clinical Research, Rare Diseases, Transplantation, Rehabilitation, Organ Transplantation, Kidney Disease, 7.1 Individual care needs, Management of diseases and conditions, Renal and urogenital, Good Health and Well Being, Adult, COVID-19, Humans, Intensive Care Units, Kidney Transplantation, Middle Aged, Outcome Assessment, Health Care, Retrospective Studies, SARS-CoV-2, Transplant Recipients, ERACODA Collaborators, Medical and Health Sciences, Surgery, Clinical sciences, Immunology
Abstract

BackgroundKidney transplant patients are at high risk for coronavirus disease 2019 (COVID-19)-related mortality. However, limited data are available on longer-term clinical, functional, and mental health outcomes in patients who survive COVID-19.MethodsWe analyzed data from adult kidney transplant patients in the European Renal Association COVID-19 Database who presented with COVID-19 between February 1, 2020, and January 31, 2021.ResultsWe included 912 patients with a mean age of 56.7 (±13.7) y. 26.4% were not hospitalized, 57.5% were hospitalized without need for intensive care unit (ICU) admission, and 16.1% were hospitalized and admitted to the ICU. At 3 mo follow-up survival was 82.3% overall, and 98.8%, 84.2%, and 49.0%, respectively, in each group. At 3 mo follow-up biopsy-proven acute rejection, need for renal replacement therapy, and graft failure occurred in the overall group in 0.8%, 2.6%, and 1.8% respectively, and in 2.1%, 10.6%, and 10.6% of ICU-admitted patients, respectively. Of the surviving patients, 83.3% and 94.4% reached their pre-COVID-19 physician-reported functional and mental health status, respectively, within 3 mo. Of patients who had not yet reached their prior functional and mental health status, their treating physicians expected that 79.6% and 80.0%, respectively, still would do so within the coming year. ICU admission was independently associated with a low likelihood to reach prior functional and mental health status.ConclusionsIn kidney transplant recipients alive at 3-mo follow-up, clinical, physician-reported functional, and mental health recovery was good for both nonhospitalized and hospitalized patients. Recovery was, however, less favorable for patients who had been admitted to the ICU.

Published
2022

11. Availability, coverage, and scope of health information systems for kidney care across world countries and regions.

Author

See, Emily J, Bello, Aminu K, Levin, Adeera, Lunney, Meaghan, Osman, Mohamed A, Ye, Feng, Ashuntantang, Gloria E, Bellorin-Font, Ezequiel, Benghanem Gharbi, Mohammed, Davison, Sara, Ghnaimat, Mohammad, Harden, Paul, Htay, Htay, Jha, Vivekanand, Kalantar-Zadeh, Kamyar, Kerr, Peter G, Klarenbach, Scott, Kovesdy, Csaba P, Luyckx, Valerie, Neuen, Brendon, O'Donoghue, Donal, Ossareh, Shahrzad, Perl, Jeffrey, Rashid, Harun Ur, Rondeau, Eric, Syed, Saad, Sola, Laura, Tchokhonelidze, Irma, Tesar, Vladimir, Tungsanga, Kriang, Kazancioglu, Rumeyza Turan, Wang, Angela Yee-Moon, Yang, Chih-Wei, Zemchenkov, Alexander, Zhao, Ming-Hui, Jager, Kitty J, Caskey, Fergus, Perkovic, Vlado, Jindal, Kailash K, Okpechi, Ikechi G, Tonelli, Marcello, Feehally, John, Harris, David C, and Johnson, David W

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Health Services, Clinical Research, Patient Safety, Prevention, Kidney Disease, Health and social care services research, 8.1 Organisation and delivery of services, Renal and urogenital, Good Health and Well Being, Cross-Sectional Studies, Developing Countries, Health Information Systems, Humans, Kidney, Renal Insufficiency, Chronic, chronic kidney disease, end-stage kidney disease, health information systems, kidney replacement therapy, registries, Urology & Nephrology, Clinical sciences
Abstract

BackgroundHealth information systems (HIS) are fundamental tools for the surveillance of health services, estimation of disease burden and prioritization of health resources. Several gaps in the availability of HIS for kidney disease were highlighted by the first iteration of the Global Kidney Health Atlas.MethodsAs part of its second iteration, the International Society of Nephrology conducted a cross-sectional global survey between July and October 2018 to explore the coverage and scope of HIS for kidney disease, with a focus on kidney replacement therapy (KRT).ResultsOut of a total of 182 invited countries, 154 countries responded to questions on HIS (85% response rate). KRT registries were available in almost all high-income countries, but few low-income countries, while registries for non-dialysis chronic kidney disease (CKD) or acute kidney injury (AKI) were rare. Registries in high-income countries tended to be national, in contrast to registries in low-income countries, which often operated at local or regional levels. Although cause of end-stage kidney disease, modality of KRT and source of kidney transplant donors were frequently reported, few countries collected data on patient-reported outcome measures and only half of low-income countries recorded process-based measures. Almost no countries had programs to detect AKI and practices to identify CKD-targeted individuals with diabetes, hypertension and cardiovascular disease, rather than members of high-risk ethnic groups.ConclusionsThese findings confirm significant heterogeneity in the global availability of HIS for kidney disease and highlight important gaps in their coverage and scope, especially in low-income countries and across the domains of AKI, non-dialysis CKD, patient-reported outcomes, process-based measures and quality indicators for KRT service delivery.

Published
2021

12. Clinical triage of patients on kidney replacement therapy presenting with COVID-19: an ERACODA registry analysis

Author

Mitra, Sandip, Jayanti, Anuradha, Vart, Priya, Coca, Armando, Gallieni, Maurizio, Øvrehus, Marius Altern, Midtvedt, Karsten, Abd ElHafeez, Samar, Gandolfini, Iliaria, Büttner, Stefan, Franssen, Casper FM, Hemmelder, Marc H, van der Net, Jeroen B, Essig, Marie, du Buf-Vereijken, Peggy WG, van Ginneken, Betty, Vogt, Nanda Maas Liffert, van Jaarsveld, Brigit C, Jager, Kitty J, Bemelman, Frederike J, Klingenberg-Salahova, Farah, Heenan-Vos, Frederiek, Vervloet, Marc G, Nurmohamed, Azam, Abramowicz, Daniel, Maoujoud, Sabine Verhofstede Omar, Malfait, Thomas, Fialova, Jana, Melilli, Edoardo, Favà, Alexandre, Cruzado, Josep M, Perez, Nuria Montero, Lips, Joy, Krepel, Harmen, Adilovic, Harun, Hengst, Maaike, Rydzewski, rzej, Gellert, Ryszard, Oliveira, João, Alferes, Daniela G, Zakharova, Elena V, Ambuehl, Patrice Max, Walker, rea, Winzeler, Rebecca, Lepeytre, Fanny, Rabaté, Clémentine, Rostoker, Guy, Marques, Sofia, Azasevac, Tijana, Katicic, Dajana, Dam, Marc ten, Krüger, Thilo, Brzosko, Szymon, Zanen, Adriaan L, Logtenberg, Susan JJ, Fricke, Lutz, Slebe, Jeroen JP, Kemlin, Delphine, van de Wetering, Jacqueline, Reinders, Marlies EJ, Eiselt, Jaromir, Kielberger, Lukas, El-Wakil, Hala S, Verhoeven, Martine AM, Canal, Cristina, Facundo, Carme, Ramos, Ana M, Debska-Slizien, Alicja, Veldhuizen, Nicoline MH, Tigka, Eirini, Konsta, Maria Anna Polyzou, Panagoutsos, Stylianos, Mallamaci, Francesca, Postorino, Adele, Cambareri, Francesco, Covic, Adrian, Matceac, Irina, Nistor, Ionut, Cordos, Monica, Groeneveld, JHM, van Buren, Jolanda Jousma Marjolijn, Pereira, Fritz Diekmann Tiago Assis, Santos, Augusto Cesar S, Arias-Cabrales, Carlos, Crespo, Marta, Llinàs-Mallol, Laura, Buxeda, Anna, Tàrrega, Carla Burballa, Redondo-Pachon, Dolores, Jimenez, Maria Dolores Arenas, Hofstra, Julia M, Franco, Antonio, Arroyo, David, Rodríguez-Ferrero, Maria Luisa, Manzanos, Sagrario Balda, Haridian Sosa Barrios, R, Ávila, Gonçalo, Laranjinha, Ivo, Mateus, Catarina, and Lemahieu, Wim

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Transplantation, Clinical Research, Kidney Disease, Prevention, Renal and urogenital, Good Health and Well Being, Aged, COVID-19, Hospitalization, Humans, Oxygen Saturation, Registries, Renal Replacement Therapy, SARS-CoV-2, Triage, dialysis, kidney, mortality, second presentation, transplantation, ERACODA Collaborators, Urology & Nephrology, Clinical sciences
Abstract

BackgroundPatients on kidney replacement therapy (KRT) are at very high risk of coronavirus disease 2019 (COVID-19). The triage pathway for KRT patients presenting to hospitals with varying severity of COVID-19 illness remains ill-defined. We studied the clinical characteristics of patients at initial and subsequent hospital presentations and the impact on patient outcomes.MethodsThe European Renal Association COVID-19 Database (ERACODA) was analysed for clinical and laboratory features of 1423 KRT patients with COVID-19 either hospitalized or non-hospitalized at initial triage and those re-presenting a second time. Predictors of outcomes (hospitalization, 28-day mortality) were then determined for all those not hospitalized at initial triage.ResultsAmong 1423 KRT patients with COVID-19 [haemodialysis (HD), n = 1017; transplant, n = 406), 25% (n = 355) were not hospitalized at first presentation due to mild illness (30% HD, 13% transplant). Of the non-hospitalized patients, only 10% (n = 36) re-presented a second time, with a 5-day median interval between the two presentations (interquartile range 2-7 days). Patients who re-presented had worsening respiratory symptoms, a decrease in oxygen saturation (97% versus 90%) and an increase in C-reactive protein (26 versus 73 mg/L) and were older (72 vs 63 years) compared with those who did not return a second time. The 28-day mortality between early admission (at first presentation) and deferred admission (at second presentation) was not significantly different (29% versus 25%; P = 0.6). Older age, prior smoking history, higher clinical frailty score and self-reported shortness of breath at first presentation were identified as risk predictors of mortality when re-presenting after discharge at initial triage.ConclusionsThis study provides evidence that KRT patients with COVID-19 and mild illness can be managed effectively with supported outpatient care and with vigilance of respiratory symptoms, especially in those with risk factors for poor outcomes. Our findings support a risk-stratified clinical approach to admissions and discharges of KRT patients presenting with COVID-19 to aid clinical triage and optimize resource utilization during the ongoing pandemic.

Published
2021

13. Current status of health systems financing and oversight for end-stage kidney disease care: a cross-sectional global survey.

Author

Yeung, Emily, Bello, AK, Levin, Adeera, Lunney, Meaghan, Osman, Mohamed A, Ye, Feng, Ashuntantang, Gloria, Bellorin-Font, Ezequiel, Benghanem Gharbi, Mohammed, Davison, Sara, Ghnaimat, Mohammad, Harden, Paul, Jha, Vivekanand, Kalantar-Zadeh, Kamyar, Kerr, Peter, Klarenbach, Scott, Kovesdy, Csaba, Luyckx, Valerie, Neuen, Brendon, O'Donoghue, Donal, Ossareh, Shahrzad, Perl, Jeffrey, Ur Rashid, Harun, Rondeau, Eric, See, Emily, Saad, Syed, Sola, Laura, Tchokhonelidze, Irma, Tesar, Vladimir, Tungsanga, Kriang, Turan Kazancioglu, Rumeyza, Wang, Angela Yee-Moon, Wiebe, Natasha, Yang, Chih-Wei, Zemchenkov, Alexander, Zhao, Minhui, Jager, Kitty J, Caskey, Fergus, Perkovic, Vlado, Jindal, Kailash, Okpechi, Ikechi G, Tonelli, Marcello, Feehally, John, Harris, David Ch, and Johnson, David

Subjects
Humans, Kidney Failure, Chronic, Renal Dialysis, Cross-Sectional Studies, Developing Countries, Health Services Accessibility, chronic renal failure, dialysis, end stage renal failure, epidemiology, health economics, organisation of health services, Clinical Sciences, Public Health and Health Services, Other Medical and Health Sciences
Abstract

ObjectivesThe Global Kidney Health Atlas (GKHA) is a multinational, cross-sectional survey designed to assess the current capacity for kidney care across all world regions. The 2017 GKHA involved 125 countries and identified significant gaps in oversight, funding and infrastructure to support care for patients with kidney disease, especially in lower-middle-income countries. Here, we report results from the survey for the second iteration of the GKHA conducted in 2018, which included specific questions about health financing and oversight of end-stage kidney disease (ESKD) care worldwide.SettingA cross-sectional global survey.ParticipantsKey stakeholders from 182 countries were invited to participate. Of those, stakeholders from 160 countries participated and were included.Primary outcomesPrimary outcomes included cost of kidney replacement therapy (KRT), funding for dialysis and transplantation, funding for conservative kidney management, extent of universal health coverage, out-of-pocket costs for KRT, within-country variability in ESKD care delivery and oversight systems for ESKD care. Outcomes were determined from a combination of desk research and input from key stakeholders in participating countries.Results160 countries (covering 98% of the world's population) responded to the survey. Economic factors were identified as the top barrier to optimal ESKD care in 99 countries (64%). Full public funding for KRT was more common than for conservative kidney management (43% vs 28%). Among countries that provided at least some public coverage for KRT, 75% covered all citizens. Within-country variation in ESKD care delivery was reported in 40% of countries. Oversight of ESKD care was present in all high-income countries but was absent in 13% of low-income, 3% of lower-middle-income, and 10% of upper-middle-income countries.ConclusionSignificant gaps and variability exist in the public funding and oversight of ESKD care in many countries, particularly for those in low-income and lower-middle-income countries.

Published
2021

14. Regional Variation in Hemoglobin Distribution Among Individuals With CKD: the ISN International Network of CKD Cohorts

Author

Ahn, Curie, Berger, Stefan P., Caskey, Fergus J., Cho, Min Hyun, Cho, Heeyeon, Dekker, Friedo W., Diwan, Vishal, Drechsler, Christiane, Eckardt, Kai-Uwe, Evans, Marie, Ferreiro, Alejandro, Floege, Jürgen, Gadola, Liliana, Haller, Hermann, Han, Kyung Hee, Healy, Helen G., Heerspink, Hiddo Lambers, Hemmelder, Marc, Hiemstra, Thomas, Hilbrands, Luuk, Kim, Seong Heon, Klyprayong, Pinkaew, Köttgen, Anna, Kronenberg, Florian, Lamadrid, Veronica, Lee, Joo Hoo, Mark, Patrick, Matheson, Matt, Mi, Eun, Noppakun, Kajohnsak, Oefner, Peter, Panaput, Thanachai, Park, Young Seo, Prokosch, Hans-Ulrich, Reis, André, Rios, Pablo, Rosivall, Laszlo, Rotmans, Joris I., Sackeyfio, Alfred, Sangthawan, Pornpen, Schmid, Matthias, Shin, Jae Il, Silavarino, Ricardo, Sitter, Thomas, Sommerer, Claudia, Szymczak, Maciej, Torino, Claudia, Toth, Janos, van Ittersum, Frans J., Venuthurupalli, Sree Krishna, Verhaar, Marianne C., Wang, Zaimin, Wanner, Christoph, Wiecek, Andrzej, Wolf, Gunter, de Zeeuw, Dick, Zhang, Luxia, Zheng, Yuyan, Zhao, Ming-Hui, Zietse, Robert, Canney, Mark, Induruwage, Dilshani, Tang, Mila, Alencar de Pinho, Natalia, Er, Lee, Zhao, Yinshan, Djurdjev, Ognjenka, Ahn, Yo Han, Behnisch, Rouven, Calice-Silva, Viviane, Chesnaye, Nicholas C., de Borst, Martin H., Dember, Laura M., Dionne, Janis, Ebert, Natalie, Eder, Susanne, Fenton, Anthony, Fukagawa, Masafumi, Furth, Susan L., Hoy, Wendy E., Imaizumi, Takahiro, Jager, Kitty J., Jha, Vivekanand, Kang, Hee Gyung, Kitiyakara, Chagriya, Mayer, Gert, Oh, Kook-Hwan, Onu, Ugochi, Pecoits-Filho, Roberto, Reichel, Helmut, Richards, Anna, Schaefer, Franz, Schaeffner, Elke, Scheppach, Johannes B., Sola, Laura, Ulasi, Ifeoma, Wang, Jinwei, Yadav, Ashok K., Zhang, Jianzhen, Feldman, Harold I., Taal, Maarten W., Stengel, Bénédicte, and Levin, Adeera

Published
2023
Full Text
View/download PDF

15. Peritoneal Dialysis Use and Practice Patterns: An International Survey Study

Author

Cho, Yeoungjee, Bello, Aminu K, Levin, Adeera, Lunney, Meaghan, Osman, Mohamed A, Ye, Feng, Ashuntantang, Gloria E, Bellorin-Font, Ezequiel, Gharbi, Mohammed Benghanem, Davison, Sara N, Ghnaimat, Mohammad, Harden, Paul, Htay, Htay, Jha, Vivekanand, Kalantar-Zadeh, Kamyar, Kerr, Peter G, Klarenbach, Scott, Kovesdy, Csaba P, Luyckx, Valerie, Neuen, Brendon, O'Donoghue, Donal, Ossareh, Shahrzad, Perl, Jeffrey, Rashid, Harun Ur, Rondeau, Eric, See, Emily J, Saad, Syed, Sola, Laura, Tchokhonelidze, Irma, Tesar, Vladimir, Tungsanga, Kriang, Kazancioglu, Rumeyza Turan, Yee-Moon Wang, Angela, Yang, Chih-Wei, Zemchenkov, Alexander, Zhao, Ming-Hui, Jager, Kitty J, Caskey, Fergus J, Jindal, Kailash K, Okpechi, Ikechi G, Tonelli, Marcello, Harris, David C, and Johnson, David W

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Clinical Research, Kidney Disease, Aging, Health Services, Administrative Personnel, Cost Sharing, Costs and Cost Analysis, Cross-Sectional Studies, Delivery of Health Care, Developed Countries, Developing Countries, Health Expenditures, Health Policy, Health Services Accessibility, Humans, Internationality, Kidney Failure, Chronic, Nephrologists, Nephrology, Outcome Assessment, Health Care, Patient Reported Outcome Measures, Peritoneal Dialysis, Physicians, Practice Patterns, Physicians', Quality of Health Care, Surveys and Questionnaires, Epidemiology, RRT modality, access to health care, affordability of health care, end-stage renal disease, global survey, health care delivery, health care disparities, health policy, home dialysis, international differences, kidney failure, peritoneal dialysis, renal replacement therapy, Public Health and Health Services, Urology & Nephrology, Clinical sciences
Abstract

Rationale & objectiveApproximately 11% of people with kidney failure worldwide are treated with peritoneal dialysis (PD). This study examined PD use and practice patterns across the globe.Study designA cross-sectional survey.Setting & participantsStakeholders including clinicians, policy makers, and patient representatives in 182 countries convened by the International Society of Nephrology between July and September 2018.OutcomesPD use, availability, accessibility, affordability, delivery, and reporting of quality outcome measures.Analytical approachDescriptive statistics.ResultsResponses were received from 88% (n=160) of countries and there were 313 participants (257 nephrologists [82%], 22 non-nephrologist physicians [7%], 6 other health professionals [2%], 17 administrators/policy makers/civil servants [5%], and 11 others [4%]). 85% (n=156) of countries responded to questions about PD. Median PD use was 38.1 per million population. PD was not available in 30 of the 156 (19%) countries responding to PD-related questions, particularly in countries in Africa (20/41) and low-income countries (15/22). In 69% of countries, PD was the initial dialysis modality for≤10% of patients with newly diagnosed kidney failure. Patients receiving PD were expected to pay 1% to 25% of treatment costs, and higher (>75%) copayments (out-of-pocket expenses incurred by patients) were more common in South Asia and low-income countries. Average exchange volumes were adequate (defined as 3-4 exchanges per day or the equivalent for automated PD) in 72% of countries. PD quality outcome monitoring and reporting were variable. Most countries did not measure patient-reported PD outcomes.LimitationsLow responses from policy makers; limited ability to provide more in-depth explanations underpinning outcomes from each country due to lack of granular data; lack of objective data.ConclusionsLarge inter- and intraregional disparities exist in PD availability, accessibility, affordability, delivery, and reporting of quality outcome measures around the world, with the greatest gaps observed in Africa and South Asia.

Published
2021

16. Hemodialysis Use and Practice Patterns: An International Survey Study

Author

Htay, Htay, Bello, Aminu K, Levin, Adeera, Lunney, Meaghan, Osman, Mohamed A, Ye, Feng, Ashuntantang, Gloria E, Bellorin-Font, Ezequiel, Gharbi, Mohammed Benghanem, Davison, Sara N, Ghnaimat, Mohammad, Harden, Paul, Jha, Vivekanand, Kalantar-Zadeh, Kamyar, Kerr, Peter G, Klarenbach, Scott, Kovesdy, Csaba P, Luyckx, Valerie A, Neuen, Brendon, O'Donoghue, Donal, Ossareh, Shahrzad, Perl, Jeffrey, Rashid, Harun Ur, Rondeau, Eric, See, Emily J, Saad, Syed, Sola, Laura, Tchokhonelidze, Irma, Tesar, Vladimir, Tungsanga, Kriang, Kazancioglu, Rumeyza Turan, Yee-Moon Wang, Angela, Yang, Chih-Wei, Zemchenkov, Alexander, Zhao, Ming-Hui, Jager, Kitty J, Caskey, Fergus J, Perkovic, Vlado, Jindal, Kailash K, Okpechi, Ikechi G, Tonelli, Marcello, Harris, David C, and Johnson, David W

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Clinical Research, Kidney Disease, Prevention, Good Health and Well Being, Arteriovenous Shunt, Surgical, Cost Sharing, Costs and Cost Analysis, Cross-Sectional Studies, Developed Countries, Developing Countries, Health Expenditures, Health Services Accessibility, Humans, Internationality, Kidney Failure, Chronic, Nephrology, Patient Reported Outcome Measures, Practice Patterns, Physicians', Quality of Health Care, Renal Dialysis, Surveys and Questionnaires, Transportation of Patients, ESKD care, HD accessibility, HD affordability, HD availability, Hemodialysis, RRT modality, end-stage kidney disease, funding for HD services, global survey, health care delivery, health care disparities, health policy, international differences, kidney failure, quality of HD services, renal replacement therapy, Public Health and Health Services, Urology & Nephrology, Clinical sciences
Abstract

Rationale & objectiveHemodialysis (HD) is the most common form of kidney replacement therapy. This study aimed to examine the use, availability, accessibility, affordability, and quality of HD care worldwide.Study designA cross-sectional survey.Setting & participantsStakeholders (clinicians, policy makers, and consumer representatives) in 182 countries were convened by the International Society of Nephrology from July to September 2018.OutcomesUse, availability, accessibility, affordability, and quality of HD care.Analytical approachDescriptive statistics.ResultsOverall, representatives from 160 (88%) countries participated. Median country-specific use of maintenance HD was 298.4 (IQR, 80.5-599.4) per million population (pmp). Global median HD use among incident patients with kidney failure was 98.0 (IQR, 81.5-140.8) pmp and median number of HD centers was 4.5 (IQR, 1.2-9.9) pmp. Adequate HD services (3-4 hours 3 times weekly) were generally available in 27% of low-income countries. Home HD was generally available in 36% of high-income countries. 32% of countries performed monitoring of patient-reported outcomes; 61%, monitoring of small-solute clearance; 60%, monitoring of bone mineral markers; 51%, monitoring of technique survival; and 60%, monitoring of patient survival. At initiation of maintenance dialysis, only 5% of countries used an arteriovenous access in almost all patients. Vascular access education was suboptimal, funding for vascular access procedures was not uniform, and copayments were greater in countries with lower levels of income. Patients in 23% of the low-income countries had to pay >75% of HD costs compared with patients in only 4% of high-income countries.LimitationsA cross-sectional survey with possibility of response bias, social desirability bias, and limited data collection preventing in-depth analysis.ConclusionsIn summary, findings reveal substantial variations in global HD use, availability, accessibility, quality, and affordability worldwide, with the lowest use evident in low- and lower-middle-income countries.

Published
2021

18. Serum Potassium and Risk of Death or Kidney Replacement Therapy in Older People With CKD Stages 4-5: Eight-Year Follow-up

Author

Schneider, Andreas, Torp, Anke, Iwig, Beate, Perras, Boris, Marx, Christian, Drechsler, Christiane, Blaser, Christof, Wanner, Christoph, Emde, Claudia, Krieter, Detlef, Fuchs, Dunja, Irmler, Ellen, Platen, Eva, Schmidt-Gürtler, Hans, Schlee, Hendrik, Naujoks, Holger, Schlee, Ines, Cäsar, Sabine, Beige, Joachim, Röthele, Jochen, Mazur, Justyna, Hahn, Kai, Blouin, Katja, Neumeier, Katrin, Anding-Rost, Kirsten, Schramm, Lothar, Hopf, Monika, Wuttke, Nadja, Frischmuth, Nikolaus, Ichtiaris, Pawlos, Kirste, Petra, Schulz, Petra, Aign, Sabine, Biribauer, Sandra, Manan, Sherin, Röser, Silke, Heidenreich, Stefan, Palm, Stephanie, Schwedler, Susanne, Delrieux, Sylke, Renker, Sylvia, Schättel, Sylvia, Stephan, Theresa, Schmiedeke, Thomas, Weinreich, Thomas, Leimbach, Til, Stövesand, Torsten, Bahner, Udo, Seeger, Wolfgang, Cupisti, Adamasco, Sagliocca, Adelia, Ferraro, Alberto, Mele, Alessandra, Naticchia, Alessandro, Còsaro, Alex, Ranghino, Andrea, Stucchi, Andrea, Pignataro, Angelo, De Blasio, Antonella, Pani, Antonello, Tsalouichos, Aris, Antonio, Bellasi, Alessandra, Butti, Abaterusso, Cataldo, Somma, Chiara, D’alessandro, Claudia, Torino, Claudia, de Rooij, Esther N.M., de Fijter, Johan W., Le Cessie, Saskia, Hoorn, Ewout J., Jager, Kitty J., Chesnaye, Nicholas C., Evans, Marie, Windahl, Karin, Caskey, Fergus J., Szymczak, Maciej, Dekker, Friedo W., and Hoogeveen, Ellen K.

Published
2023
Full Text
View/download PDF

19. Defining measures of kidney function in observational studies using routine health care data: methodological and reporting considerations

Author

Carrero, Juan Jesus, Fu, Edouard L., Vestergaard, Søren V., Jensen, Simon Kok, Gasparini, Alessandro, Mahalingasivam, Viyaasan, Bell, Samira, Birn, Henrik, Heide-Jørgensen, Uffe, Clase, Catherine M., Cleary, Faye, Coresh, Josef, Dekker, Friedo W., Gansevoort, Ron T., Hemmelgarn, Brenda R., Jager, Kitty J., Jafar, Tazeen H., Kovesdy, Csaba P., Sood, Manish M., Stengel, Bénédicte, Christiansen, Christian F., Iwagami, Masao, and Nitsch, Dorothea

Published
2023
Full Text
View/download PDF

21. Time trends in preemptive kidney transplantation in Europe: an era registry study

Author

Kramer, Anneke, primary, Boenink, Rianne, additional, Mercado Vergara, Cynthia G, additional, Bell, Samira, additional, Kerschbaum, Julia, additional, Rodríguez Arévalo, Olga L, additional, Mazuecos, Auxiliadora, additional, de Vries, Aiko P J, additional, Reisæter, Anna V, additional, Wong, Esther H S, additional, Lundgren, Torbjörn, additional, Valentin, María O, additional, Alvarez, Flor Angel Ordoñez, additional, Melilli, Edoardo, additional, Finne, Patrik, additional, Segelmark, Mårten, additional, Couchoud, Cécile, additional, Sørensen, Søren S, additional, Ferraro, Pietro Manuel, additional, Arnol, Miha, additional, Arici, Mustafa, additional, Ortiz, Alberto, additional, Jager, Kitty J, additional, Abramowicz, Daniel, additional, Stel, Vianda S, additional, and Hellemans, Rachel, additional

Published
2024
Full Text
View/download PDF

22. #364 Patient characteristics, treatment history and prognosis of adult survivors of childhood kidney replacement therapy—an ERA Registry study

Author

de Sousa, Iris R Montez, primary, Bonthuis, Marjolein, additional, Kramer, Anneke, additional, Ortiz, Alberto, additional, Rydell, Helena, additional, Groothoff, Jaap W, additional, Bakkaloglu, Sevcan A, additional, Sørensen, Søren S, additional, Stel, Vianda, additional, and Jager, Kitty J, additional

Published
2024
Full Text
View/download PDF

23. #2509 Longitudinal haemoglobin levels and mortality in an elderly population with advanced chronic kidney disease: insights from the EQUAL Study

Author

Lombardi, Gianmarco, primary, Chesnaye, Nicholas, additional, Caskey, Fergus, additional, Dekker, Friedo W, additional, Evans, Marie, additional, Torino, Claudia, additional, Szymczak, Maciej, additional, Wanner, Christoph, additional, Gambaro, Giovanni, additional, Stel, Vianda, additional, Ferraro, Pietro Manuel, additional, and Jager, Kitty J, additional

Published
2024
Full Text
View/download PDF

25. #2477 Longitudinal serum bicarbonate and mortality risk in older patients with advanced chronic kidney disease: analyses from the EQUAL cohort

Author

Lombardi, Gianmarco, primary, Chesnaye, Nicholas, additional, Caskey, Fergus, additional, Dekker, Friedo W, additional, Evans, Marie, additional, Torino, Claudia, additional, Szymczak, Maciej, additional, Wanner, Christoph, additional, Gambaro, Giovanni, additional, Stel, Vianda, additional, Jager, Kitty J, additional, and Ferraro, Pietro Manuel, additional

Published
2024
Full Text
View/download PDF

26. #325 Prescribing patterns in older people with advanced chronic kidney disease approaching the end of life

Author

Letts, Matthew, primary, Chesnaye, Nicholas, additional, Pippias, Maria, additional, Caskey, Fergus, additional, Jager, Kitty J, additional, Dekker, Friedo W, additional, Evans, Marie, additional, Torino, Claudia, additional, Szymczak, Maciej, additional, Wanner, Christoph, additional, Hole, Barnaby, additional, and Hayward, Samantha, additional

Published
2024
Full Text
View/download PDF

27. Biomarkers in clinical epidemiology studies

Author

Zoccali, Carmine, primary, Tripepi, Giovanni, additional, Stel, Vianda, additional, Fu, Eduard L, additional, Mallamaci, Francesca, additional, Dekker, Friedo, additional, and Jager, Kitty J, additional

Published
2024
Full Text
View/download PDF

28. A toolkit for ISN’s registry initiative, SharE-RR

Author

Pippias, Maria, primary, Abeysekera, Rajitha A., additional, Arruebo, Silvia, additional, Davids, M. Razeen, additional, Damster, Sandrine, additional, Gonzales-Bedat, Maria C., additional, Hanafusa, Norio, additional, Hoshino, Junichi, additional, Hradsky, Anne, additional, Irish, Georgina L., additional, Jager, Kitty J., additional, Karam, Sabine, additional, Kumar, Vivek, additional, McDonald, Stephen P., additional, Rosa-Diez, Guillermo J., additional, Tannor, Elliot K., additional, Wetmore, James B., additional, and Caskey, Fergus J., additional

Published
2024
Full Text
View/download PDF

29. The association between TMAO, CMPF, and clinical outcomes in advanced chronic kidney disease: results from the European QUALity (EQUAL) Study

Author

Dai, Lu, Massy, Ziad A, Stenvinkel, Peter, Chesnaye, Nicholas C, Larabi, Islam Amine, Alvarez, Jean Claude, Caskey, Fergus J, Torino, Claudia, Porto, Gaetana, Szymczak, Maciej, Krajewska, Magdalena, Drechsler, Christiane, Wanner, Christoph, Jager, Kitty J, Dekker, Friedo W, Evenepoel, Pieter, and Evans, Marie

Published
2022
Full Text
View/download PDF

30. Predicting Kidney Failure, Cardiovascular Disease and Death in Advanced CKD Patients

Author

Cupisti, Adamasco, Sagliocca, Adelia, Ferraro, Alberto, Musiała, Aleksandra, Mele, Alessandra, Naticchia, Alessandro, Còsaro, Alex, Woodman, Alistair, Ranghino, Andrea, Stucchi, Andrea, Jonsson, Andreas, Schneider, Andreas, Pignataro, Angelo, Schrander, Anita, Torp, Anke, McKeever, Anna, Szymczak, Anna, Blom, Anna-Lena, De Blasio, Antonella, Pani, Antonello, Tsalouichos, Aris, Ullah, Asad, McLaren, Barbara, van Dam, Bastiaan, Iwig, Beate, Antonio, Bellasi, Di Iorio, Biagio Raffaele, Rogland, Björn, Perras, Boris, Alessandra, Butti, Harron, Camille, Wallquist, Carin, Siegert, Carl, Barrett, Carla, Gaillard, Carlo, Garofalo, Carlo, Abaterusso, Cataldo, Beerenhout, Charles, O'Toole, Charlotte, Somma, Chiara, Marx, Christian, Summersgill, Christina, Blaser, Christof, D'alessandro, Claudia, Emde, Claudia, Zullo, Claudia, Pozzi, Claudio, Geddes, Colin, Verburgh, Cornelis, Bergamo, Daniela, Ciurlino, Daniele, Motta, Daria, Glowski, Deborah, McGlynn, Deborah, Vargas, Denes, Krieter, Detlef, Russo, Domenico, Fuchs, Dunja, Sands, Dympna, Hoogeveen, Ellen, Irmler, Ellen, Dimény, Emöke, Favaro, Enrico, Platen, Eva, Olczyk, Ewelina, Hoorn, Ewout, Vigotti, Federica, Ansali, Ferruccio, Conte, Ferruccio, Cianciotta, Francesca, Giacchino, Francesca, Cappellaio, Francesco, Pizzarelli, Francesco, Sundelin, Fredrik, Uhlin, Fredrik, Greco, Gaetano, Roy, Geena, Porto, Gaetana, Bigatti, Giada, Marinangeli, Giancarlo, Cabiddu, Gianfranca, Hirst, Gillian, Fumagalli, Giordano, Caloro, Giorgia, Piccoli, Giorgina, Capasso, Giovanbattista, Gambaro, Giovanni, Tognarelli, Giuliana, Bonforte, Giuseppe, Conte, Giuseppe, Toscano, Giuseppe, Del Rosso, Goffredo, Welander, Gunilla, Augustyniak-Bartosik, Hanna, Boots, Hans, Schmidt-Gürtler, Hans, King, Hayley, McNally, Helen, Schlee, Hendrik, Boom, Henk, Naujoks, Holger, Masri-Senghor, Houda, Murtagh, Hugh, Rayner, Hugh, Miśkowiec-Wiśniewska, Ilona, Schlee, Ines, Capizzi, Irene, Hernandez, Isabel Bascaran, Baragetti, Ivano, Manitius, Jacek, Turner, Jane, Eijgenraam, Jan-Willem, Kooman, Jeroen, Beige, Joachim, Pondel, Joanna, Wilcox, Joanne, Berdeprado, Jocelyn, Röthele, Jochen, Wong, Jonathan, Rotmans, Joris, Banda, Joyce, Mazur, Justyna, Hahn, Kai, Jędrzejak, Kamila, Nowańska, Katarzyna, Blouin, Katja, Neumeier, Katrin, Jones, Kirsteen, Anding-Rost, Kirsten, Gröntoft, Knut-Christian, Oldrizzi, Lamberto, Haydock, Lesley, Vogt, Liffert, Wilkinson, Lily, Gesualdo, Loreto, Schramm, Lothar, Biancone, Luigi, Nowak, Łukasz, Raasveld, Maarten, Durlik, Magdalena, Magnano, Manuela, Vervloet, Marc, Ricardi, Marco, Carmody, Margaret, Di Bari, Maria, Laudato, Maria, Sirico, Maria Luisa, Stendahl, Maria, Svensson, Maria, Weetman, Maria, van Buren, Marjolijn, Joinson, Martin, Ferraresi, Martina, Dutton, Mary, van Diepen, Merel, Matthews, Michael, Provenzano, Michele, Hopf, Monika, Malaguti, Moreno, Wuttke, Nadja, Morgan, Neal, Palmieri, Nicola, Frischmuth, Nikolaus, Bleakley, Nina, Murrone, Paola, Cockwell, Paul, Leurs, Paul, Roderick, Paul, Voskamp, Pauline, Kashioulis, Pavlos, Ichtiaris, Pawlos, Blankestijn, Peter, Kirste, Petra, Schulz, Petra, Mason, Phil, Kalra, Philip, Cirillo, Pietro, Dattolo, Pietro, Acampora, Pina, Sajith, Rincy, Nigro, Rita, Boero, Roberto, Scarpioni, Roberto, Sicoli, Rosa, Malandra, Rosella, Aign, Sabine, Cäsar, Sabine, van Esch, Sadie, Chapman, Sally, Biribauer, Sandra, Navjee, Santee, Crosbie, Sarah, Brown, Sharon, Tickle, Sheila, Manan, Sherin, Röser, Silke, Savoldi, Silvana, Bertoli, Silvio, Borrelli, Silvio, Boorsma, Siska, Heidenreich, Stefan, Melander, Stefan, Maxia, Stefania, Maffei, Stefano, Mangano, Stefano, Palm, Stephanie, Konings, Stijn, Mathavakkannan, Suresh, Schwedler, Susanne, Delrieux, Sylke, Renker, Sylvia, Schättel, Sylvia, Dorota, Szyszkowska, Cicchetti, Teresa, Nieszporek, Teresa, Stephan, Theresa, Schmiedeke, Thomas, Weinreich, Thomas, Leimbach, Til, Rappa, Tiziana, Almquist, Tora, Stövesand, Torsten, Bahner, Udo, Jensen, Ulrika, Palazzo, Valentina, De Simone, Walter, Seeger, Wolfgang, Kuan, Ying, Heleniak, Zbigniew, Aydin, Zeynep, Ramspek, Chava L., Boekee, Rosemarijn, Evans, Marie, Heimburger, Olof, Snead, Charlotte M., Caskey, Fergus J., Torino, Claudia, Szymczak, Maciej, Krajewska, Magdalena, Drechsler, Christiane, Wanner, Christoph, Chesnaye, Nicholas C., Jager, Kitty J., Dekker, Friedo W., Snoeijs, Maarten G.J., and Rotmans, Joris I.

Published
2022
Full Text
View/download PDF

32. Increasing access to integrated ESKD care as part of universal health coverage

Author

Harris, David CH, Davies, Simon J, Finkelstein, Fredric O, Jha, Vivekanand, Donner, Jo-Ann, Abraham, Georgi, Bello, Aminu K, Caskey, Fergus J, Garcia, Guillermo Garcia, Harden, Paul, Hemmelgarn, Brenda, Johnson, David W, Levin, Nathan W, Luyckx, Valerie A, Martin, Dominique E, McCulloch, Mignon I, Moosa, Mohammed Rafique, O’Connell, Philip J, Okpechi, Ikechi G, Filho, Roberto Pecoits, Shah, Kamal D, Sola, Laura, Swanepoel, Charles, Tonelli, Marcello, Twahir, Ahmed, van Biesen, Wim, Varghese, Cherian, Yang, Chih-Wei, Zuniga, Carlos, Summit, Working Groups of the International Society of Nephrology’s 2nd Global Kidney Health, Abu Alfa, Ali K, Aljubori, Harith M, Alrukhaimi, Mona N, Andreoli, Sharon P, Ashuntantang, Gloria, Bellorin-Font, Ezequiel, Bernieh, Bassam, Ibhais, Fuad M, Blake, Peter G, Brown, Mark, Brown, Edwina, Bunnag, Sakarn, Chan, Tak Mao, Chen, Yuqing, Granado, Rolando Claure-Del, Claus, Stefaan, Collins, Allan, Couchoud, Cecile, Cueto-Manzano, Alfonso, Cullis, Brett, Douthat, Walter, Dreyer, Gavin, Eiam-Ong, Somchai, Eke, Felicia U, Feehally, John, Ghnaimat, Mohammad A, Goh, BakLeong, Hassan, Mohamed H, Hou, Fan Fan, Jager, Kitty, Kalantar-Zadeh, Kamyar, Kazancioglu, Rumeyza T, Levin, Adeera, Liew, Adrian, McKnight, Marla, Mengistu, Yewondwassesn Tadesse, Morton, Rachael L, Muller, Elmi, Murtagh, Fliss EM, Naicker, Saraladevi, Nangaku, Masaomi, Niang, Abdou, Obrador, Gregorio T, Ossareh, Shahrzad, Perl, Jeffrey, Rahman, Muhibur, Rashid, Harun Ur, Richards, Marie, Rondeau, Eric, Sahay, Manisha, Saleh, Abdulkarim, Schneditz, Daniel, Tchokhonelidze, Irma, Tesar, Vladimir, Trask, Michele, Tungsanga, Kriang, Vachharajani, Tushar, Walker, Rachael C, Walker, Robert, Were, Anthony JO, Yao, Qiang, Yeates, Karen, Yu, Xueqing, Zakharova, Elena, Zemchenkov, Alexander, and Zhao, Ming-Hui

Subjects
Clinical Research, Health Services, Behavioral and Social Science, Kidney Disease, Health and social care services research, 8.1 Organisation and delivery of services, 8.3 Policy, ethics, and research governance, Good Health and Well Being, Quality Education, Conservative Treatment, Developing Countries, Global Burden of Disease, Global Health, Health Occupations, Health Planning, Health Policy, Health Services Accessibility, Health Workforce, Humans, Kidney Failure, Chronic, Patient Advocacy, Renal Replacement Therapy, Universal Health Insurance, advocacy, conservative care, dialysis, end-stage kidney disease, ESKD, funding, training, transplantation, universal health coverage, Working Groups of the International Society of Nephrology’s 2nd Global Kidney Health Summit, Clinical Sciences, Urology & Nephrology
Abstract

The global nephrology community recognizes the need for a cohesive strategy to address the growing problem of end-stage kidney disease (ESKD). In March 2018, the International Society of Nephrology hosted a summit on integrated ESKD care, including 92 individuals from around the globe with diverse expertise and professional backgrounds. The attendees were from 41 countries, including 16 participants from 11 low- and lower-middle-income countries. The purpose was to develop a strategic plan to improve worldwide access to integrated ESKD care, by identifying and prioritizing key activities across 8 themes: (i) estimates of ESKD burden and treatment coverage, (ii) advocacy, (iii) education and training/workforce, (iv) financing/funding models, (v) ethics, (vi) dialysis, (vii) transplantation, and (viii) conservative care. Action plans with prioritized lists of goals, activities, and key deliverables, and an overarching performance framework were developed for each theme. Examples of these key deliverables include improved data availability, integration of core registry measures and analysis to inform development of health care policy; a framework for advocacy; improved and continued stakeholder engagement; improved workforce training; equitable, efficient, and cost-effective funding models; greater understanding and greater application of ethical principles in practice and policy; definition and application of standards for safe and sustainable dialysis treatment and a set of measurable quality parameters; and integration of dialysis, transplantation, and comprehensive conservative care as ESKD treatment options within the context of overall health priorities. Intended users of the action plans include clinicians, patients and their families, scientists, industry partners, government decision makers, and advocacy organizations. Implementation of this integrated and comprehensive plan is intended to improve quality and access to care and thereby reduce serious health-related suffering of adults and children affected by ESKD worldwide.

Published
2019

33. Status of care for end stage kidney disease in countries and regions worldwide: international cross sectional survey

Author

Bello, Aminu K, Levin, Adeera, Lunney, Meaghan, Osman, Mohamed A, Ye, Feng, Ashuntantang, Gloria E, Bellorin-Font, Ezequiel, Benghanem Gharbi, Mohammed, Davison, Sara N, Ghnaimat, Mohammad, Harden, Paul, Htay, Htay, Jha, Vivekanand, Kalantar-Zadeh, Kamyar, Kerr, Peter G, Klarenbach, Scott, Kovesdy, Csaba P, Luyckx, Valerie A, Neuen, Brendon L, O'Donoghue, Donal, Ossareh, Shahrzad, Perl, Jeffrey, Rashid, Harun Ur, Rondeau, Eric, See, Emily, Saad, Syed, Sola, Laura, Tchokhonelidze, Irma, Tesar, Vladimir, Tungsanga, Kriang, Turan Kazancioglu, Rumeyza, Wang, Angela Yee-Moon, Wiebe, Natasha, Yang, Chih-Wei, Zemchenkov, Alexander, Zhao, Ming-Hui, Jager, Kitty J, Caskey, Fergus, Perkovic, Vlado, Jindal, Kailash K, Okpechi, Ikechi G, Tonelli, Marcello, Feehally, John, Harris, David C, and Johnson, David W

Subjects
Clinical Research, Health Services, Kidney Disease, Renal and urogenital, Cross-Sectional Studies, Developing Countries, Global Health, Health Services Accessibility, Humans, Kidney Failure, Chronic, Nephrology, Renal Replacement Therapy, Clinical Sciences, Public Health and Health Services, General & Internal Medicine
Abstract

ObjectiveTo determine the global capacity (availability, accessibility, quality, and affordability) to deliver kidney replacement therapy (dialysis and transplantation) and conservative kidney management.DesignInternational cross sectional survey.SettingInternational Society of Nephrology (ISN) survey of 182 countries from July to September 2018.ParticipantsKey stakeholders identified by ISN's national and regional leaders.Main outcome measuresMarkers of national capacity to deliver core components of kidney replacement therapy and conservative kidney management.ResultsResponses were received from 160 (87.9%) of 182 countries, comprising 97.8% (7338.5 million of 7501.3 million) of the world's population. A wide variation was found in capacity and structures for kidney replacement therapy and conservative kidney management-namely, funding mechanisms, health workforce, service delivery, and available technologies. Information on the prevalence of treated end stage kidney disease was available in 91 (42%) of 218 countries worldwide. Estimates varied more than 800-fold from 4 to 3392 per million population. Rwanda was the only low income country to report data on the prevalence of treated disease; 5 (

Published
2019

34. Mortality Trends After Transfer From Peritoneal Dialysis to Hemodialysis

Author

Combes, Gill, Firanek, Catherine, Gomez, Rafael, Jha George, Vivek, Madero, Magdalena, Masakane, Ikuto, Misra, Madhukar, McDonald, Stephen, Mitra, Sandip, Moraes, Thyago, Mukhopadhyay, Puma, Sloand, James, Tong, Allison, Szeto, Cheuk-Chun, Nadeau-Fredette, Annie-Claire, Sukul, Nidhi, Lambie, Mark, Perl, Jeffrey, Davies, Simon, Johnson, David W., Robinson, Bruce, Van Biesen, Wim, Kramer, Anneke, Jager, Kitty J., Saran, Rajiv, Pisoni, Ronald, and Chan, Christopher T.

Published
2022
Full Text
View/download PDF

36. Patient-Reported Measures and Lifestyle Are Associated With Deterioration in Nutritional Status in CKD Stage 4-5: The EQUAL Cohort Study

Author

Windahl, Karin, Irving, Gerd Faxén, Almquist, Tora, Lidén, Maarit Korkeila, Stenvinkel, Peter, Chesnaye, Nicholas C., Drechsler, Christiane, Szymczak, Maciej, Krajewska, Magdalena, Fu, Edouard L., Torino, Claudia, Porto, Gaetana, Roderick, Paul, Caskey, Fergus J., Wanner, Christoph, Dekker, Friedo W., Jager, Kitty J., and Evans, Marie

Published
2022
Full Text
View/download PDF

38. Decoy receptors as biomarkers for exploring aetiology and designing new therapies.

Author

Zoccali, Carmine, Tripepi, Giovanni, Stel, Vianda, Fu, Edouard L, Mallamaci, Francesca, Dekker, Friedo, and Jager, Kitty J

Abstract

Soluble decoy receptors (DR) are circulating proteins that act as molecular traps for ligands that modulate various signalling pathways. These proteins can be exploited as biomarkers and, in some cases, as drugs in various disease contexts. Inflammation is a key area where DRs have shown significant potential. By binding to pro-inflammatory cytokines, inflammatory DRs, such as soluble tumour necrosis factor receptors (sTNFRs), can inhibit downstream inflammatory signalling. This modulation of the inflammatory response holds promise for therapeutic interventions in various inflammatory conditions, including cardiovascular and chronic kidney diseases. Soluble DRs for advanced glycation end products (sRAGE) bind to advanced glycation end products (AGEs), reducing their detrimental effects on vascular function and atherosclerosis. High circulating sRAGE levels are associated with a lower risk for CV events, highlighting the potential of these soluble receptors for assessing the role of AGEs in CV diseases and managing the attendant risk. DRs may serve as biomarkers and therapeutic agents to advance our understanding of disease mechanisms and improve patients' outcomes. Their ability to modulate signalling pathways in a controlled manner opens up new opportunities for therapeutic interventions in various diseases, ranging from inflammation to cardiovascular and renal disorders. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

39. Sex differences in CKD risk factors across ethnic groups.

Author

Vosters, Taryn G, Kingma, Frouke M, Stel, Vianda S, Born, Bert-Jan H van den, Huisman, Brechje J M V, Ittersum, Frans J van, Jager, Kitty J, Vogt, Liffert, and Valkengoed, Irene G M van

Subjects
SEX factors in disease, ETHNIC groups, DIABETIC nephropathies
Abstract

This article discusses a study on sex differences in chronic kidney disease (CKD) risk factors among different ethnic groups. The study found that men had higher rates of hypertension and diabetes, while obesity rates were higher in women. Hypertension was identified as the strongest contributor to CKD across all ethnic groups. The study emphasizes the importance of considering sex and ethnic differences in CKD risk factors for effective prevention and management strategies. The article also provides data on health indicators in Morocco and presents findings from a study on CKD prevalence in the Netherlands. The authors suggest that additional factors may contribute to sex differences in CKD prevalence in specific ethnic subgroups. The study was funded by various organizations and has been approved by the AMC Ethical Review Board. [Extracted from the article]

Published
2024
Full Text
View/download PDF

40. Improving the prognosis of patients with severely decreased glomerular filtration rate (CKD G4+): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference

Author

Eckardt, Kai-Uwe, Bansal, Nisha, Coresh, Josef, Evans, Marie, Grams, Morgan E, Herzog, Charles A, James, Matthew T, Heerspink, Hiddo JL, Pollock, Carol A, Stevens, Paul E, Tamura, Manjula Kurella, Tonelli, Marcello A, Wheeler, David C, Winkelmayer, Wolfgang C, Cheung, Michael, Hemmelgarn, Brenda R, Participants, Conference, Abu-Alfa, Ali K, Anand, Shuchi, Arici, Mustafa, Ballew, Shoshana H, Block, Geoffrey A, Burgos-Calderon, Rafael, Charytan, David M, Das-Gupta, Zofia, Dwyer, Jamie P, Fliser, Danilo, Froissart, Marc, Gill, John S, Griffith, Kathryn E, Harris, David C, Huffman, Kate, Inker, Lesley A, Jager, Kitty J, Jun, Min, Kalantar-Zadeh, Kamyar, Kasiske, Bertrand L, Kovesdy, Csaba P, Krane, Vera, Lamb, Edmund J, Lerma, Edgar V, Levey, Andrew S, Levin, Adeera, Mauro, Juan Carlos Julián, Nash, Danielle M, Navaneethan, Sankar D, O’Donoghue, Donal, Obrador, Gregorio T, Pecoits-Filho, Roberto, Robinson, Bruce M, Schäffner, Elke, Segev, Dorry L, Stengel, Bénédicte, Stenvinkel, Peter, Tangri, Navdeep, Tentori, Francesca, Tsukamoto, Yusuke, Turakhia, Mintu P, Vazquez, Miguel A, Wang, Angela Yee-Moon, and Williams, Amy W

Subjects
Heart Disease, Cardiovascular, Clinical Research, Kidney Disease, Management of diseases and conditions, 7.3 Management and decision making, Renal and urogenital, Good Health and Well Being, Clinical Decision-Making, Consensus, Evidence-Based Medicine, Glomerular Filtration Rate, Humans, Kidney, Nephrology, Prognosis, Renal Insufficiency, Chronic, Risk Factors, Severity of Illness Index, chronic kidney disease, kidney failure, prediction, prognosis, progression, supportive care, Conference Participants, Clinical Sciences, Urology & Nephrology
Abstract

Patients with severely decreased glomerular filtration rate (GFR) (i.e., chronic kidney disease [CKD] G4+) are at increased risk for kidney failure, cardiovascular disease (CVD) events (including heart failure), and death. However, little is known about the variability of outcomes and optimal therapeutic strategies, including initiation of kidney replacement therapy (KRT). Kidney Disease: Improving Global Outcomes (KDIGO) organized a Controversies Conference with an international expert group in December 2016 to address this gap in knowledge. In collaboration with the CKD Prognosis Consortium (CKD-PC) a global meta-analysis of cohort studies (n = 264,515 individuals with CKD G4+) was conducted to better understand the timing of clinical outcomes in patients with CKD G4+ and risk factors for different outcomes. The results confirmed the prognostic value of traditional CVD risk factors in individuals with severely decreased GFR, although the risk estimates vary for kidney and CVD outcomes. A 2- and 4-year model of the probability and timing of kidney failure requiring KRT was also developed. The implications of these findings for patient management were discussed in the context of published evidence under 4 key themes: management of CKD G4+, diagnostic and therapeutic challenges of heart failure, shared decision-making, and optimization of clinical trials in CKD G4+ patients. Participants concluded that variable prognosis of patients with advanced CKD mandates individualized, risk-based management, factoring in competing risks and patient preferences.

Published
2018

41. A randomized multicenter trial on a lung ultrasound–guided treatment strategy in patients on chronic hemodialysis with high cardiovascular risk

Author

Zoccali, Carmine, Torino, Claudia, Mallamaci, Francesca, Sarafidis, Pantelis, Papagianni, Aikaterini, Ekart, Robert, Hojs, Radovan, Klinger, Marian, Letachowicz, Krzysztof, Fliser, Danilo, Seiler-Mußler, Sarah, Lizzi, Fabio, Wiecek, Andrzej, Miskiewicz, Agata, Siamopoulos, Kostas, Balafa, Olga, Slotki, Itzchak, Shavit, Linda, Stavroulopoulos, Aristeidis, Covic, Adrian, Siriopol, Dimitrie, Massy, Ziad A., Seidowsky, Alexandre, Battaglia, Yuri, Martinez-Castelao, Alberto, Polo-Torcal, Carolina, Coudert-Krier, Marie-Jeanne, Rossignol, Patrick, Fiaccadori, Enrico, Regolisti, Giuseppe, Hannedouche, Thierry, Bachelet, Thomas, Jager, Kitty J., Dekker, Friedo W., Tripepi, Rocco, Tripepi, Giovanni, Gargani, Luna, Sicari, Rosa, Picano, Eugenio, and London, Gérard Michel

Published
2021
Full Text
View/download PDF

42. The safety of a low protein diet in older adults with advanced chronic kidney disease

Author

Windahl, Karin, primary, Chesnaye, Nicholas C, additional, Irving, Gerd Faxén, additional, Stenvinkel, Peter, additional, Almquist, Tora, additional, Lidén, Maarit Korkeila, additional, Drechsler, Christiane, additional, Szymczak, Maciej, additional, Krajewska, Magdalena, additional, de Rooij, Esther, additional, Torino, Claudia, additional, Porto, Gaetana, additional, Caskey, Fergus J, additional, Wanner, Christoph, additional, Jager, Kitty J, additional, Dekker, Friedo W, additional, and Evans, Marie, additional

Published
2024
Full Text
View/download PDF

43. A comparison of the epidemiology of kidney replacement therapy between Europe and the United States: 2021 data of the ERA Registry and the USRDS

Author

Stel, Vianda S, primary, Boenink, Rianne, additional, Astley, Megan E, additional, Boerstra, Brittany A, additional, Radunovic, Danilo, additional, Skrunes, Rannveig, additional, Ruiz San Millán, Juan C, additional, Slon Roblero, Maria F, additional, Bell, Samira, additional, Ucio Mingo, Pablo, additional, ten Dam, Marc A G J, additional, Ambühl, Patrice M, additional, Resic, Halima, additional, Rodríguez Arévalo, Olga Lucia, additional, Aresté-Fosalba, Nuria, additional, Tort i Bardolet, Jaume, additional, Lassalle, Mathilde, additional, Trujillo-Alemán, Sara, additional, Indridason, Olafur S, additional, Artamendi, Marta, additional, Finne, Patrik, additional, Rodríguez Camblor, Marta, additional, Nitsch, Dorothea, additional, Hommel, Kristine, additional, Moustakas, George, additional, Kerschbaum, Julia, additional, Lausevic, Mirjana, additional, Jager, Kitty J, additional, Ortiz, Alberto, additional, and Kramer, Anneke, additional

Published
2024
Full Text
View/download PDF

44. Growth in children on kidney replacement therapy: a review of data from patient registries

Author

Bonthuis, Marjolein, Harambat, Jérôme, Jager, Kitty J., and Vidal, Enrico

Subjects
Growth disorders -- Risk factors -- Statistics, Chronic kidney failure -- Care and treatment -- Complications and side effects -- Statistics, Pediatric research, Health
Abstract

Growth retardation is a major complication in children with chronic kidney disease (CKD) and on kidney replacement therapy (KRT). Conversely, better growth in childhood CKD is associated with an improvement in several hard morbidity-mortality endpoints. Data from pediatric international registries has demonstrated that improvements in the overall conservative management of CKD, the search for optimal dialysis, and advances in immunosuppression and kidney transplant techniques have led to a significant improvement of final height over time. Infancy still remains a critical period for adequate linear growth, and the loss of stature during the first years of life influences final height. Preliminary new original data from the European Society for Paediatric Nephrology/European Renal Association-European Dialysis and Transplant Association (ESPN/ERA-EDTA) Registry confirm an association between the final height and the height attained at 2 years in children on KRT., Author(s): Marjolein Bonthuis [sup.1] , Jérôme Harambat [sup.2] , Kitty J. Jager [sup.1] , Enrico Vidal [sup.3] Author Affiliations: (1) ESPN/ERA-EDTA Registry, Department of Medical Informatics, Amsterdam Public Health Research [...]

Published
2021
Full Text
View/download PDF

46. Supplemented ERA-EDTA Registry data evaluated the frequency of dialysis, kidney transplantation, and comprehensive conservative management for patients with kidney failure in Europe

Author

Stel, Vianda S., de Jong, Rianne W., Kramer, Anneke, Andrusev, Anton M., Baltar, José M., Barbullushi, Myftar, Bell, Samira, Castro de la Nuez, Pablo, Cernevskis, Harijs, Couchoud, Cécile, De Meester, Johan, Eriksen, Bjørn O., Gârneaţă, Liliana, Golan, Eliezer, Helve, Jaakko, Hemmelder, Marc H., Hommel, Kristine, Ioannou, Kyriakos, Jarraya, Faiçal, Kantaria, Nino, Kerschbaum, Julia, Komissarov, Kirill S., Magaz, Ángela, Mercadal, Lucile, Ots-Rosenberg, Mai, Pálsson, Runólfur, Rahmel, Axel, Rydell, Helena, Savino, Manuela, Seyahi, Nurhan, Slon Roblero, Maria F., Stojceva-Taneva, Olivera, van der Tol, Arjan, Vazelov, Evgueniy S., Ziginskiene, Edita, Zurriaga, Óscar, Vanholder, Raymond C., Massy, Ziad A., and Jager, Kitty J.

Published
2021
Full Text
View/download PDF

48. Ten-year trends in epidemiology and outcomes of pediatric kidney replacement therapy in Europe: data from the ESPN/ERA-EDTA Registry

Author

Bonthuis, Marjolein, Vidal, Enrico, Bjerre, Anna, Aydoğ, Özlem, Baiko, Sergey, Garneata, Liliana, Guzzo, Isabella, Heaf, James G., Jahnukainen, Timo, Lilien, Marc, Mallett, Tamara, Mirescu, Gabriel, Mochanova, Elena A., Nüsken, Eva, Rascher, Katherine, Roussinov, Dimitar, Szczepanska, Maria, Tsimaratos, Michel, Varvara, Askiti, Verrina, Enrico, Veselinović, Bojana, Jager, Kitty J., and Harambat, Jérôme

Published
2021
Full Text
View/download PDF

49. Results from the ERA-EDTA Registry indicate a high mortality due to COVID-19 in dialysis patients and kidney transplant recipients across Europe

Author

Jager, Kitty J., Kramer, Anneke, Chesnaye, Nicholas C., Couchoud, Cécile, Sánchez-Álvarez, J. Emilio, Garneata, Liliana, Collart, Fréderic, Hemmelder, Marc H., Ambühl, Patrice, Kerschbaum, Julia, Legeai, Camille, del Pino y Pino, María Dolores, Mircescu, Gabriel, Mazzoleni, Lionel, Hoekstra, Tiny, Winzeler, Rebecca, Mayer, Gert, Stel, Vianda S., Wanner, Christoph, Zoccali, Carmine, and Massy, Ziad A.

Published
2020
Full Text
View/download PDF

50. Data from the ERA-EDTA Registry were examined for trends in excess mortality in European adults on kidney replacement therapy

Author

Boenink, Rianne, Stel, Vianda S., Waldum-Grevbo, Bård E., Collart, Frederic, Kerschbaum, Julia, Heaf, James G., de Meester, Johan, Finne, Patrik, García-Marcos, Sergio A., Evans, Marie, Ambühl, Patrice M., Arici, Mustafa, Ayav, Carole, Steenkamp, Retha, Cases, Aleix, Traynor, Jamie P., Palsson, Runolfur, Zoccali, Carmine, Massy, Ziad A., Jager, Kitty J., and Kramer, Anneke

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results